Doxazosin-structure (Doxazosin Structure)
Doxazosin Tablet
Product Images NDC 0904-5523
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 0904-5523). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure1.jpg (Figure1)
Bottle Label (Image 01)
This is a medication package containing 100 tablets of Doxazosin, USP, which is dispensed only with a patient information leaflet. The package is labeled with the NDC code 0904-5522-61 along with a warning for temperature storage and an expiration date of 2120125. The package is in a unit dose format and cannot be sold separately as this is a prescription drug.*
Bottle Label (Image 02)
This is a medication called Doxazosin Tablets, which is available only with a prescription. The package contains 100 tablets, and the NDC code is 0904552361. The text also mentions a patient information leaflet, but nothing specific can be inferred from the given information. It also includes storage instructions and some precautions for users.*
Bottle Label (Image 03)
This is a description for a drug called Doxazosin in tablet form. The medication is available in unit doses of 100 tablets with a strength of 4 L. The NDC number is 0904-5524-61. The pharmacist is instructed to dispense the medication without the patient information leaflet. The rest of the text is not-readable.*
Table3.jpg (Table3)
The text appears to be a summary of the effectiveness data in placebo-controlled trials for a medication called Doxazosin. The medication's maximum flow symptom score and rate are recorded in mL/sec, with baseline change data compared to a placebo. The summary also includes information about three different studies that were conducted, noting the questionnaire used and changes made to the endpoint. However, there seems to be some missing information or errors in the text, making it difficult to fully understand the results.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
